Damora Therapeutics(DMRA)
$24.30+1.32 (+5.74%)
DMRA
Damora Therapeutics financials statements
$24.30
At close:+1.32 (+5.74%)
Want to see DMRA full AI Analyst Report?
Damora Therapeutics (DMRA) Ratios
345 Followers
Damora Therapeutics Ratios
DMRA's free cash flow for Q3 2026 was $-17.23M. For the 2026 fiscal year, DMRA's free cash flow was increased by $0.00 and operating cash flow was $-17.23M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 12.98 | 14.07 | 6.31 | 5.75 | 24.23 |
| Quick Ratio | 12.98 | 14.07 | 6.31 | 5.75 | 24.23 |
| Cash Ratio | 12.84 | 11.84 | 3.68 | 2.95 | 13.77 |
| Solvency Ratio | -10.41 | -7.99 | -6.36 | -5.35 | -10.28 |
| Operating Cash Flow Ratio | -0.34 | -15.56 | -6.33 | -3.87 | -11.51 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -1551.92 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 240.28M | $ 14.18M | $ 30.88M | $ 52.48M | $ 105.11M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.08 | 0.01 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.00 | 0.10 | 0.01 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.00 | 0.09 | 0.01 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.09 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.08 | 1.18 | 1.18 | 1.19 | 1.04 |
| Debt Service Coverage Ratio | 0.00 | -1771.50 | 0.00 | -145.60 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -146.78 | 0.00 |
| Debt to Market Cap | 0.00 | 0.25 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.05 | 1.24 | 0.23 | 1.20 | 0.84 |
| Net Debt to EBITDA | 1.23 | 0.60 | 0.60 | 0.53 | 1.19 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.02% | 100.19% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 99.49% | 126.64% | 96.10% | 100.68% | 99.09% |
| Return on Assets (ROA) | -80.54% | -125.14% | -100.32% | -84.20% | -42.35% |
| Return on Equity (ROE) | -87.29% | -148.15% | -118.61% | -99.79% | -44.15% |
| Return on Capital Employed (ROCE) | -87.69% | -106.04% | -123.17% | -98.59% | -44.38% |
| Return on Invested Capital (ROIC) | -87.69% | -105.96% | -122.48% | -97.84% | -44.23% |
| Return on Tangible Assets | -80.54% | -125.14% | -100.32% | -84.20% | -42.35% |
| Earnings Yield | -669.07% | -398.44% | -200.45% | -210.89% | -67.61% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.48 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -760.25 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 760.25 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -4.93 | -16.09 | -34.73 | -42.24 | -51.77 |
| Free Cash Flow Per Share | -4.93 | -16.09 | -34.73 | -42.43 | -51.99 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | -219.04 | -234.57 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | -219.04 | -234.57 |
| Operating Cash Flow Coverage Ratio | -98.91 | -13.00 | -148.24 | -53.40 | -61.76 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -21.45% | -346.10% | -192.93% | -147.60% | -68.63% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.15 | -0.25 | -0.50 | -0.47 | -1.48 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.13 | 0.37 | 0.59 | 0.47 | 0.65 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.66 | -0.29 | -0.52 | -0.68 | -1.46 |
| Price-to-Operating Cash Flow Ratio | -4.66 | -0.29 | -0.52 | -0.68 | -1.46 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 0.01 | 0.01 | -0.02 | -0.03 |
| Enterprise Value Multiple | 1.08 | 0.35 | 0.06 | 0.05 | -0.29 |
| Enterprise Value | -226.19M | -7.36M | -2.08M | -2.76M | 14.83M |
| EV to EBITDA | 1.08 | 0.35 | 0.06 | 0.05 | -0.29 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 33.63 | 0.40 | 0.06 | 0.06 | -0.28 |
| EV to Operating Cash Flow | 33.63 | 0.40 | 0.06 | 0.06 | -0.28 |
| Tangible Book Value Per Share | 176.36 | 12.51 | 30.42 | 60.76 | 116.01 |
| Shareholders’ Equity Per Share | 176.36 | 12.51 | 30.42 | 60.76 | 116.01 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -153.95 | -18.53 | -36.08 | -60.63 | -51.22 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.05 | 1.01 | 0.99 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.03 | 0.87 | 0.96 | 0.70 | 1.01 |
Currency in USD

